← Back to Clinical Trials
Recruiting NCT06987877

NCT06987877 Efficacy of Routine Saline Flushing in the Prevention of Nephrostomy Tube Obstructions: A Pilot Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06987877
Status Recruiting
Phase
Sponsor Brigham and Women's Hospital
Condition Nephrostomy
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2026-01-01
Primary Completion 2026-12-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
No flushing of the nephrostomyFlushing of nephrostomy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2026-01-01 with a primary completion date of 2026-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators performing this research to study if routine flushing is necessary to prevent obstructions of a nephrostomy tube. This study will evaluate patients that have nephrostomy tube or will have nephrostomy tubes placed as part of their standard clinical care. If participants agree to participate in this study, participants will undergo randomized assignment to either continue to routinely flush the nephrostomy tube with normal saline or not to routinely flush the nephrostomy tube with normal saline. Participantswill be in the study for approximately 3 months if they decide to stay for the whole study.

Eligibility Criteria

Inclusion Criteria: • Age 18-80, with planned nephrostomy tube exchange or new nephrostomy tube placement with ongoing need for a nephrostomy tube. Exclusion Criteria: * Current local infection * History of anaphylaxis to iodinated contrast * Pregnant or intent to become pregnant during the study * Irreversible coagulopathy * Planned for definitive treatment for the clinical indication of the nephrostomy tube prior to 12-week post-intervention. * Planned routine exchange prior to 12 weeks after nephrostomy tube exchange or placement procedure * Complete sensory loss below T10 dermatome.

Contact & Investigator

Central Contact

Yan Epelboym, MD, MPH

✉ yepelboym@bwh.harvard.edu

📞 617-732-4763

Principal Investigator

Yan Epelboym, MD, MPH

PRINCIPAL INVESTIGATOR

MGB

Frequently Asked Questions

Who can join the NCT06987877 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Nephrostomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06987877 currently recruiting?

Yes, NCT06987877 is actively recruiting participants. Contact the research team at yepelboym@bwh.harvard.edu for enrollment information.

Where is the NCT06987877 trial being conducted?

This trial is being conducted at Boston, United States.

Who is sponsoring the NCT06987877 clinical trial?

NCT06987877 is sponsored by Brigham and Women's Hospital. The principal investigator is Yan Epelboym, MD, MPH at MGB. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology